This $145,745 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Oklahoma State University to investigate how the Chlamydia trachomatis bacterium, the leading cause of sexually transmitted infections worldwide, modulates the host's immune response and inflammasome activation. The research aims to elucidate the mechanism by which a specific Chlamydia protein, CT226, interacts with host...
This Project Grant award of $156,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research by Thomas Jefferson University to characterize the process of homotypic fusion in the bacterium Chlamydia muridarum. The goal is to determine how this fusion process contributes to the virulence and pathogenesis of Chlamydia infections, which are a leading cause of sexually transmitted...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $399,100 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) Division. This 2-year project will investigate how the pathogen Chlamydia trachomatis manipulates the host cell protein PICALM to facilitate its own replication and survival, while minimizing host cell stress. The research aims...
This $617,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to delineate the molecular function and contributions to species-specific infection biology of putative glycosyltransferase "cytotoxin" proteins in Chlamydia bacteria. The University of Kentucky Research Foundation, the awardee, has applied genetic and biochemical approaches to investigate...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research into the regulation of divisome assembly in the obligate intracellular pathogen Chlamydia trachomatis. The total award is $782,795.00 over a period of 5 years, starting on Jun 17, 2025. The research aims to define the molecular mechanisms that regulate divisome function and the polarized division...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $423,500.00 to investigate the role(s) of chlamydial polymorphic membrane proteins (PMPs) during infection with Chlamydia trachomatis. The award was granted to The University of Kentucky Research Foundation on July 1, 2025 and is set to run through June 30, 2027. The key objectives are to delineate the specific function(s) of PmpI...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $195,896 to the University of Washington to conduct research on prevention strategies for Chlamydia trachomatis (CT) infections. The key objectives are to: 1) characterize the frequency and factors associated with antibiotic use among men who have sex with men in Seattle, to inform the potential utility of doxycycline prophylaxis; 2) develop...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Idaho. The grant will fund research to better understand the developmental cycle of chlamydial bacteria, which cause various infectious diseases in humans. Specifically, the project aims to develop a CRISPR-based knockdown screen to assess the role of essential genes in regulating chlamydial...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to investigate the use of a selective TNFR2 blockade to prevent infertility associated with chlamydia pelvic inflammatory disease (PID). The $335,000 award, effective August 1, 2024 through July 31, 2026, will enable the establishment of a humanized TNFA/TNFR1/TNFR2 (HTNF) mouse model to...
The Applied Research Foundation of West Virginia received a $444,000 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research program) to study the effects of stress on Chlamydia infections in a mouse model. The research aims to define the mechanisms by which stress may suppress the immune system and increase the intensity of Chlamydia genital infection and its associated immunopathologies. Key aspects of the project...
CHARACTERIZING THE FUNCTION OF CYCLIC DI-AMP ON CHLAMYDIAL GROWTH AND DIFFERENTIATION - PROJECT SUMMARY: CHARACTERIZING THE FUNCTION OF CYCLIC DI-AMP ON CHLAMYDIAL GROWTH AND DIFFERENTIATION CHLAMYDIA IS AN OBLIGATE INTRACELLULAR BACTERIAL PATHOGEN THAT CAUSES A RANGE OF SERIOUS DISEASES IN HUMANS. IN DEVELOPED COUNTRIES, CHLAMYDIA TRACHOMATIS IS THE PRIMARY CAUSE OF BACTERIAL SEXUALLY TRANSMITTED INFECTIONS (STI). INDEED, RECENT REPORTS FROM THE CENTERS FOR DISEASE CONTROL HIGHLIGHT THE INCREASING INCIDENCE OF STIS, WITH CHLAMYDIA INFECTIONS CONSISTENTLY OUTPACING ALL OTHER BACTERIAL CAUSES. IN DEVELOPING COUNTRIES, C. TRACHOMATIS IS NOT ONLY A SIGNIFICANT CAUSE OF STI, BUT IT IS ALSO RESPONSIBLE FOR THE PRIMARY CAUSE OF INFECTIOUS PREVENTABLE BLINDNESS, TRACHOMA. THE MAJOR CONCERN OF CHLAMYDIAL INFECTIONS IS THAT THEY ARE OFTEN ASYMPTOMATIC AND UNDIAGNOSED, WHICH CAN LEAD TO CHRONIC SEQUELAE. THESE INCLUDE PELVIC INFLAMMATORY DISEASE, TUBAL FACTOR INFERTILITY, AND REACTIVE ARTHRITIS FOR C. TRACHOMATIS. CONSEQUENTLY, CHLAMYDIAL DISEASES REMAIN A SIGNIFICANT BURDEN ON HEALTH CARE SYSTEMS AROUND THE WORLD. IN ADAPTING TO OBLIGATE INTRACELLULAR GROWTH, CHLAMYDIA HAS SIGNIFICANTLY REDUCED ITS GENOME SIZE AND ELIMINATED GENES FROM VARIOUS PATHWAYS AS IT RELIES ON THE HOST CELL FOR ITS METABOLIC NEEDS. THIS SUGGESTS THAT THE PRESENCE OF ANY PARTICULAR GENE(S) IS CRITICAL, IF NOT ESSENTIAL, FOR ITS GROWTH AND PATHOGENESIS. IMPORTANTLY, CHLAMYDIA ALSO ALTERNATES BETWEEN DIFFERENT FUNCTIONAL AND MORPHOLOGICAL FORMS DURING ITS NORMAL GROWTH, ALSO REFERRED TO AS ITS DEVELOPMENTAL CYCLE. THESE OBSERVATIONS, COMBINED WITH ITS OBLIGATE INTRACELLULAR DEPENDENCE, MAKES CHLAMYDIA A DIFFICULT ORGANISM WITH WHICH TO WORK. HOWEVER, RECENT DEVELOPMENT OF GENETIC TOOLS TO MECHANISTICALLY STUDY CHLAMYDIAE HAVE SIGNIFICANTLY ENHANCED OUR UNDERSTANDING OF THIS PATHOGEN. RELATED TO THIS PROPOSAL IS THE OBSERVATION THAT CHLAMYDIA PRODUCES A SECOND MESSENGER COMPOUND, CYCLIC DI-AMP (C-DI-AMP), THAT IS KNOWN TO ACTIVATE HOST CELL IMMUNE-SIGNALING PATHWAYS. INTERESTINGLY, C-DI-AMP IS TYPICALLY PRODUCED IN GRAM-POSITIVE BACTERIA AND MYCOBACTERIA TO REGULATE ASPECTS OF THEIR PHYSIOLOGY AND PATHOGENESIS, YET CHLAMYDIA IS A GRAM-NEGATIVE BACTERIUM. WE PROPOSE TO INVESTIGATE WHY CHLAMYDIA PRODUCES C-DI-AMP AND HOW IT FUNCTIONS IN THE PHYSIOLOGY OF THE ORGANISM. THE FIRST PROJECT GOAL IS TO CHARACTERIZE USING GENETIC TECHNIQUES THE EFFECTS OF ALTERING C-DI-AMP PRODUCTION ON CHLAMYDIA GROWTH AND DEVELOPMENTAL CYCLE PROGRESSION. THE SECOND PROJECT GOAL IS TO IDENTIFY GENES THAT ARE REGULATED BY C-DI-AMP. RESULTS FROM THE PROPOSED STUDIES WILL ADVANCE OUR UNDERSTANDING OF THE FUNCTION OF C-DI-AMP IN CHLAMYDIAL PHYSIOLOGY AND IDENTIFY NEW TARGETS FOR DEVELOPMENT OF CHLAMYDIA-SPECIFIC TREATMENTS.